What is NDC 65145-176?

65145-176 is the product NDC for Milrinone Lactate in 5% Dextrose, Milrinone lactate .2 mg/mL injection, solution, listed with the FDA by Caplin Steriles Limited. It has 1 package NDC, shown above in 10- and 11-digit form.

Caplin Steriles Limited, NDC labeler code 65145. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Milrinone Lactate in 5% Dextrose?

3 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Milrinone Lactate in 5% Dextrose NDC 65145-176

NDC codes

FDA NDC Directory

Product NDC (as listed)65145-176Labeler and product segments. Claims need a package NDC.

Product NDC at billing width65145-0176Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
65145-176-10	6514501761065145017610	10 POUCH in 1 CASE (65145-176-10) / 1 BAG in 1 POUCH (65145-176-01) / 100 mL in 1 BAGMarketed from Jun 25, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Milrinone Lactate in 5% Dextrose
Generic name (nonproprietary): milrinone lactate in 5% dextrose
Active ingredients: Milrinone lactate — .2 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Caplin Steriles LimitedNDC labeler code 65145
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219170
Marketing start: Jun 25, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 65145-176_0c0d357c-432e-40f9-8736-a633a0e33005SPL ID 0c0d357c-432e-40f9-8736-a633a0e33005SPL set ID a2822b12-0560-49d6-ace5-2377c04425e8RxCUI 1791840, 1791842UNII 9K8XR81MO8UPC 0365145177018, 0365145176011
Pharmacologic class: Phosphodiesterase 3 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N465145017610 followed by a unit qualifier and the quantity

Package 65145-0176-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 25, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 65145-176

What is NDC 65145-176?: 65145-176 is the product NDC for Milrinone Lactate in 5% Dextrose, Milrinone lactate .2 mg/mL injection, solution, listed with the FDA by Caplin Steriles Limited. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Milrinone Lactate in 5% Dextrose.
What is the active ingredient?: Milrinone lactate.
Who is the labeler?: Caplin Steriles Limited, NDC labeler code 65145. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Milrinone Lactate in 5% Dextrose?: 3 other product NDCs are listed under this name. See all Milrinone Lactate in 5% Dextrose NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Milrinone Lactate in 5% Dextrose NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Milrinone Lactate in 5% Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Caplin Steriles Limited	65145-177	65145-0177-10
Milrinone Lactate in 5% Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Somerset Therapeutics, LLC	70069-872	70069-0872-10
Milrinone Lactate in 5% Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Somerset Therapeutics, LLC	70069-873	70069-0873-10

Other NDCs under ANDA 219170

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219170
Product	Strength	Form · route	Labeler	Product NDC
Milrinone Lactate in 5% Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Caplin Steriles Limited	65145-177
Milrinone Lactate in 5% Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Somerset Therapeutics, LLC	70069-872
Milrinone Lactate in 5% Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Somerset Therapeutics, LLC	70069-873